Loading...

Daniel M. Togasaki, MD, PhD

Title(s)Associate Professor of Clinical Neurology
Phone+1 323 442 5728
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Berkovich RR, Sokolov AY, Togasaki DM, Yakupova AA, Cesar PH, Sahai-Srivastava S. Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study. Clin Neuropharmacol. 2018 Mar/Apr; 41(2):64-69. PMID: 29474194.
      View in: PubMed
    2. Berkovich R, Togasaki DM, Cen SY, Steinman L. CD4 cell response to interval therapy with natalizumab. Ann Clin Transl Neurol. 2015 May; 2(5):570-4. PMID: 26000328.
      View in: PubMed
    3. Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50. PMID: 24366103.
      View in: PubMed
    4. Factor SA, Wolski K, Togasaki DM, Huyck S, Cantillon M, Ho TW, Hauser RA, Pourcher E. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Mov Disord. 2013 Jun; 28(6):817-20. PMID: 23589371.
      View in: PubMed
    5. Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013 Mar; 28(3):380-3. PMID: 23339054.
      View in: PubMed
    6. Vuckovic MG, Wood RI, Holschneider DP, Abernathy A, Togasaki DM, Smith A, Petzinger GM, Jakowec MW. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis. 2008 Nov; 32(2):319-27. PMID: 18718537.
      View in: PubMed
    7. Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P, Turnquist P, Vuckovic M, Fisher BE, Togasaki DM, Jakowec MW. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci. 2007 May 16; 27(20):5291-300. PMID: 17507552.
      View in: PubMed
    8. Cox H, Togasaki DM, Chen L, Langston JW, Di Monte DA, Quik M. The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Exp Neurol. 2007 May; 205(1):101-7. PMID: 17335811.
      View in: PubMed
    9. Togasaki DM, Hsu A, Samant M, Farzan B, DeLanney LE, Langston JW, Di Monte DA, Quik M. The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods. 2005 Jun 30; 145(1-2):159-66. PMID: 15922034.
      View in: PubMed
    10. Togasaki DM, Protell P, Tan LC, Langston JW, Di Monte DA, Quik M. Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology. 2005 Mar; 48(3):398-405. PMID: 15721172.
      View in: PubMed
    11. Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys. Neuroscience. 2005; 132(2):409-20. PMID: 15802193.
      View in: PubMed
    12. Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M. Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther. 2004 Nov; 311(2):770-7. PMID: 15226382.
      View in: PubMed
    13. Tan LC, Protell PH, Langston JW, Togasaki DM. The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys. Mov Disord. 2002 Sep; 17(5):902-9. PMID: 12360538.
      View in: PubMed
    14. Yee RE, Huang SC, Togasaki DM, Langston JW, Satyamurthy N, Barrio JR. Imaging and therapeutics: the role of neuronal transport in the regional specificity of L-DOPA accumulation in brain. Mol Imaging Biol. 2002 May; 4(3):208-18. PMID: 14537125.
      View in: PubMed
    15. Yee RE, Irwin I, Milonas C, Stout DB, Huang SC, Shoghi-Jadid K, Satyamurthy N, Delanney LE, Togasaki DM, Farahani KF, Delfani K, Janson AM, Phelps ME, Langston JW, Barrio JR. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord. 2001 Sep; 16(5):838-48. PMID: 11746613.
      View in: PubMed
    16. Togasaki DM, Tan L, Protell P, Di Monte DA, Quik M, Langston JW. Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol. 2001 Aug; 50(2):254-7. PMID: 11506410.
      View in: PubMed
    17. Togasaki DM, Tanner CM. Epidemiologic aspects. Adv Neurol. 2000; 82:53-9. PMID: 10624470.
      View in: PubMed
    18. Mena MA, Khan U, Togasaki DM, Sulzer D, Epstein CJ, Przedborski S. Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture. J Neurochem. 1997 Jul; 69(1):21-33. PMID: 9202290.
      View in: PubMed
    19. Dethy S, Laute MA, Togasaki DM, Przedborski S, Damhaut P, Thiry P, Hildebrand J, Goldman S. Systemic and intrastriatal theophylline have opposite effects on dopamine and dopamine metabolites measured by intrastriatal microdialysis in the rat. Neurosci Lett. 1996 Apr 26; 208(3):159-62. PMID: 8733294.
      View in: PubMed
    20. Parsons B, Togasaki DM, Kassir S, Przedborski S. Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J Neurochem. 1995 Nov; 65(5):2057-64. PMID: 7595490.
      View in: PubMed
    21. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 1995 Aug; 67(3):631-47. PMID: 7675192.
      View in: PubMed
    22. Levivier M, Holemans S, Togasaki DM, Maloteaux JM, Brotchi J, Przedborski S. Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. Neurol Res. 1994 Jun; 16(3):194-200. PMID: 7936089.
      View in: PubMed
    23. Togasaki DM, Young JG, Knott PJ. L-dihydroxyphenylalanine-induced asymmetric changes in striatal uric acid peak: determination by in vivo electrochemical detection in rats with unilateral nigrostriatal lesions. Life Sci. 1987 Sep 14; 41(11):1361-7. PMID: 3114581.
      View in: PubMed
    24. Brannan T, Weinberger J, Knott P, Taff I, Kaufmann H, Togasaki D, Nieves-Rosa J, Maker H. Direct evidence of acute, massive striatal dopamine release in gerbils with unilateral strokes. Stroke. 1987 Jan-Feb; 18(1):108-10. PMID: 3810742.
      View in: PubMed
    25. Arnold MA, Carr DB, Togasaki DM, Pian MC, Martin JB. Caffeine stimulates beta-endorphin release in blood but not in cerebrospinal fluid. Life Sci. 1982 Sep 06; 31(10):1017-24. PMID: 6290811.
      View in: PubMed